Manal Mohamed Saber
Minia University, Egypt
Title: Emap II-Induced Immune Suppression In Colorectal Cancer
Biography
Biography: Manal Mohamed Saber
Abstract
Statement of the Problem: Colorectal cancer (CRC) is being currently considered one of the most common, and deadly, malignancies in the world. Many CRC patients are likely to be immunosuppressive. Endothelial monocyte-activating polypeptide-II (EMAP-II) is a multifunctional cytokine with pro-inflammatory properties. It was demonstrated that EMAP-II induces lymphocytes apoptosis in CRC. The purpose of this study is to investigate the role of EMAP II in immune suppression in CRC.
Methodology & Theoretical Orientation: The immunosuppressive effect of EMAP II was verified by in vivo and in vitro experiments. The immunosuppressive mechanisms were analysed using flow cytometry, ELISA, immunohistochemistry, and T-lymphocytes assays.
Findings: EMAP II expression in CRC was associated with suppression of T cell activity and decreased infiltrating T cells. EMAP II blockade in mice bearing colorectal cancer reduced tumour burden and increased T cell responses. In this study, we found that colorectal cancer-infiltrating tregs expressed increased levels of EMAP II. Furthermore, EMAP-II levels correlated positively with serum IL-2 and TGF-β (p<0.001).
Conclusion & Significance: This study has demonstrated the role of EMAP II in immune suppression and the potential for immunotherapy via blocking EMAP II in CRC.